Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting
August 27, 2024 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio and SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat...
MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights Analysis 2024: Focus on 10 ML1 Inhibitor Drug In Clinical Trials, Insight By Company, Indication and Phase
August 26, 2024 11:02 ET
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2024" report has been added to ResearchAndMarkets.com's offering. ...
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
July 30, 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA)...
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
February 01, 2024 07:30 ET
|
BioRestorative Therapies, Inc
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at...
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
September 08, 2023 08:30 ET
|
BioRestorative Therapies, Inc
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE,...
AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant
August 18, 2023 10:37 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Aug. 18, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the commencement...
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
July 13, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
July 05, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
June 28, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
June 27, 2023 07:00 ET
|
BioRestorative Therapies, Inc
No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of StudyDSMB Recommendation Allows for Open Enrollment MELVILLE, N.Y., June 27, 2023 (GLOBE NEWSWIRE) --...